No Data
Huafu Securities: The demand potential in the lipid-lowering drug Industry is enormous, and several Innovative Drugs are about to receive data catalysis.
Multiple cutting-edge targets have welcomed data catalysts, with strong certainty in drug viability, suggesting to focus on domestic companies that are targeting new Innovative Drugs for lipid reduction.
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Market Cap Dropped CN¥1.1b Last Week; Private Companies Bore the Brunt
Shenzhen Salubris Pharmaceuticals (002294.SZ): Some small nucleic acid projects will be in preclinical research next year.
Gelonghui reported on December 13 that Shenzhen Salubris Pharmaceuticals (002294.SZ) recently stated in an investor relations activity that some small nucleic acid projects are in preclinical research, and further R&D progress will be announced in due course.
Shenzhen Salubris Pharmaceuticals (002294.SZ): It is expected that 1 to 2 new products will be launched each year in the future.
On December 13th, Gelonghui reported that Shenzhen Salubris Pharmaceuticals (002294.SZ) stated in a recent investor relations activity that the company is deeply engaged in the chronic disease field, focusing on cardiovascular and cerebrovascular areas, while expanding into nephrology, orthopedics, metabolism, and autoimmune fields. The company currently has 4 newly launched drugs, primarily for hypertension, nephrology, and diabetes, and it is expected that 1-2 new products will be launched each year in the future. With the aging population, the demand in these areas will also be tremendous, and the company's products have distinguishing features, leading to a good outlook.
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Price Is Out Of Tune With Earnings
Shenzhen Salubris Pharmaceuticals' Two Drugs Added to National Medical Insurance Catalog
No Data
